drugset / Trial / NCT06293742

ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants

NCT06293742

Phase 1 Completed 48 enrolled Eccogene
Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a Phase 1, open-label, non-randomized, fixed sequence study designed to evaluate the effect of ECC5004 on single dose pharmacokinetics of Atorvastatin, Rosuvastatin, Digoxin and Midazolam in healthy participants.

Timeline

Start
2024-02-08
Primary completion
2024-04-15
Completion
2024-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5004 Unknown Oral
Subject Atorvastatin Small molecule Oral
Subject Digoxin Other / unclassified Oral
Subject Midazolam Small molecule Oral
Subject Rosuvastatin Small molecule Oral